10-Q · May 14, 2026
Fortress Biotech reported a challenging Q1 2026, with revenues of $16.0 million, down 45% sequentially and missing estimates by 44.8%. The company recorded a net income of $110.4 million, influenced by the sale of a PRV…
Earnings analysis · 10-Q
FBIO earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
Fortress reported second-quarter revenue of $18.7 million, up 14% year over year, but diluted EPS declined to a loss of $0.08 from $0.45 in the prior-year quarter. Operating losses and R&D spending improved materially,…
Read full summary
Fortress reported second-quarter revenue of $18.7 million, up 14% year over year, but diluted EPS declined to a loss of $0.08 from $0.45 in the prior-year quarter. Operating losses and R&D spending improved materially, and cash reached $196.6 million, with management indicating liquidity for at least the next 12 months. The outlook remains mixed because the company continues to incur losses, has $39.6 million of debt and $16.0 million of undeclared preferred dividends, while generic competition and Emrosi litigation add commercial risk.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.08
What stood out
-
Revenue grew 14% year over year
Second-quarter revenue was $18.7 million, up 14% year over year from $16.4 million. Revenue also increased from $16.0 million in the prior quarter.
-
Operating loss narrowed materially
Six-month operating loss improved to approximately $17.7 million from $58.8 million in the comparable 2025 period, a $41.1 million reduction.
-
R&D spending fell sharply
Six-month R&D expense declined to approximately $1.3 million from $12.1 million year over year, a reduction of $10.8 million.
-
Cash balance strengthened
Cash and cash equivalents increased to $196.6 million at quarter-end, providing substantial liquidity relative to the company’s stated minimum liquidity covenant of $2.0 million.
-
Liquidity outlook remains adequate
Management stated that current cash and cash equivalents should fund operations for at least 12 months from the August 13, 2026 filing date.
-
Controls remained effective
Disclosure controls and procedures were concluded effective as of June 30, 2026, and no material change in internal control over financial reporting occurred during the quarter.
What to watch
-
Quarterly earnings returned to a loss
Diluted EPS was a loss of $0.08 versus diluted EPS of $0.45 in the prior-year quarter, reversing the prior-year quarterly profit and indicating continued earnings volatility.
-
Debt and covenant exposure
Debt outstanding, net of discount, was $39.6 million at June 30, 2026. The Oaktree agreement requires minimum liquidity of $2.0 million, and a covenant breach could trigger an event of default.
-
Persistent losses and accumulated deficit
Accumulated deficit was approximately $624.1 million at June 30, 2026, while the company reported operating losses of $17.7 million for the six months ended June 30, 2026. Management expects continued expenditures and operating costs and has not established a path to sustained profitability.
-
Preferred dividend arrears restrict financing
Series A Preferred Stock dividends remain paused at $0.1953125 per share monthly, deferring approximately $0.7 million in cash payments each month; undeclared cumulative dividends reached approximately $16.0 million at June 30, 2026. The pause also prevents use of new Form S-3 registration statements until specified conditions are met.
-
Generic competition threatens revenue
Five marketed products—Accutane, Targadox, Exelderm, Eurax and Luxamend—do not have patent protection or are not eligible for patent protection. Generic competition could reduce sales and operating income.
-
Emrosi faces generic litigation
Journey’s Emrosi patent litigation against Lupin triggered a stay of FDA approval of Lupin’s ANDA for up to 30 months. The challenged Journey patents expire in January 2039, but an adverse outcome could affect the product’s commercial prospects.
Management's outlook
No quantitative revenue or EPS guidance was provided in the 10-Q. Management stated that current cash and cash equivalents are expected to fund operations in the normal course for at least the next 12 months from filing.
Earlier filings 4
10-K · March 31, 2026
Fortress Biotech, Inc. reported significant growth with 2025 net revenue of $63.3 million, up 10.7% from $57.7 million in 2024, largely driven by new product launches including Emrosi. The company faced challenges,…
10-Q · November 14, 2025
Fortress Biotech, Inc. reported Q3 2025 earnings with net revenue of $17.6 million, representing a 20.5% increase from $14.6 million in Q3 2024. The company experienced a significant turnaround in net income, achieving…
10-Q · August 14, 2025
Fortress Biotech, Inc. reported a positive trend in Q2 2025, with revenue increasing to $16.4 million, a 10.9% rise from $14.9 million in Q2 2024. Despite this revenue growth, the company reported a diluted EPS of…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.